Izabella Wilk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Izabella Wilk has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- David Aebisher
Department of Photomedicine and Physical Chemistry, Faculty of Medicine, University of Rzeszów, 35-310 Rzeszów, Poland
6 shared publications - Dorota Bartusik-Aebisher
Department of Biochemistry and General Chemistry, Faculty of Medicine, University of Rzeszow, 35-310 Rzeszów, Poland
6 shared publications - Blassan Plackal George
Laser Research Centre, Faculty of Health Sciences, University of Johannesburg, Doornfontein, South Africa
2 shared publications - Daniel Roshan Justin Raj
English Division Science Club, Faculty of Medicine, Collegium Medicum, University of Rzeszów, 35-310 Rzeszów, Poland
1 shared publication
Latest Publications
- Open Access
- 29 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (19) , 8723
Recent Advances in Nanomedicine-Enhanced Photodynamic Therapy in Cutaneous Oncology: Melanoma-Dominant Evidence for Immunogenic Cell Death and Photoimmunotherapy
Although photodynamic therapy (PDT) is a recognised treatment for the premalignant keratinocytic lesion actinic keratosis (AK) and selected superficial skin cancers, poor photosensitiser delivery, restricted light penetration and tumour hypoxia can significantly restrict its effectiveness. Recent advances in nanomedicine are extending PDT past improved transport of the photosensitiser. These approaches can also control tumour accumulation, intracellular localisation and the generation of reactive oxygen species. The degree of tumour cell damage is not the only outcome that can be influenced by these features. They can also influence tumour-cell death and immunogenic cell death (ICD)-associated danger signalling and, in selected preclinical systems, support antigen presentation and T-cell activation. Nanomedicine-enhanced PDT has increasingly been integrated with immune-checkpoint blockade and immune adjuvants in melanoma models. In selected preclinical melanoma models, these combinations have improved local tumour control and produced antitumour effects at untreated distant or metastatic sites; functional immune memory has been demonstrated only in a smaller subset of studies using tumour-rechallenge models. Nanotechnology may further address the practical limitations of conventional PDT while improving treatment precision. This is shown by skin-directed delivery, oxygen-generating systems and theranostic platforms. However, immune-related evidence remains predominantly preclinical and melanoma-based, whereas human nanomedicine evidence in AK and basal cell carcinoma (BCC) largely concerns nanoformulation-assisted PDT rather than immune modulation. Overall, the field is progressing from nanoparticle-assisted phototoxicity towards integrated photoimmunotherapy. Treatment delivery, tumour destruction and immune activation are increasingly being considered together. Together, these findings support the continued development of nanomedicine-enhanced PDT across cutaneous oncology, while emphasising that the most advanced immune and photoimmunotherapy evidence currently remains melanoma-based.
- 29 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (19) , 8723
Open AccessRecent Advances in Nanomedicine-Enhanced Photodynamic Therapy in Cutaneous Oncology: Melanoma-Dominant Evidence for Immunogenic Cell Death and Photoimmunotherapy
Although photodynamic therapy (PDT) is a recognised treatment for the premalignant keratinocytic lesion actinic keratosis (AK) and selected superficial skin cancers, poor photosensitiser delivery, restricted light penetration and tumour hypoxia can significantly restrict its effectiveness. Recent advances in nanomedicine are extending PDT past improved transport of the photosensitiser. These approaches can also control tumour accumulation, intracellular localisation and the generation of reactive oxygen species. The degree of tumour cell damage is not the only outcome that can be influenced by these features. They can also influence tumour-cell death and immunogenic cell death (ICD)-associated danger signalling and, in selected preclinical systems, support antigen presentation and T-cell activation. Nanomedicine-enhanced PDT has increasingly been integrated with immune-checkpoint blockade and immune adjuvants in melanoma models. In selected preclinical melanoma models, these combinations have improved local tumour control and produced antitumour effects at untreated distant or metastatic sites; functional immune memory has been demonstrated only in a smaller subset of studies using tumour-rechallenge models. Nanotechnology may further address the practical limitations of conventional PDT while improving treatment precision. This is shown by skin-directed delivery, oxygen-generating systems and theranostic platforms. However, immune-related evidence remains predominantly preclinical and melanoma-based, whereas human nanomedicine evidence in AK and basal cell carcinoma (BCC) largely concerns nanoformulation-assisted PDT rather than immune modulation. Overall, the field is progressing from nanoparticle-assisted phototoxicity towards integrated photoimmunotherapy. Treatment delivery, tumour destruction and immune activation are increasingly being considered together. Together, these findings support the continued development of nanomedicine-enhanced PDT across cutaneous oncology, while emphasising that the most advanced immune and photoimmunotherapy evidence currently remains melanoma-based.
- Open Access
Acquired Chemoresistance in Colorectal Cancer: Therapy-Induced Signalling Adaptation, Cellular Plasticity and Mechanism-Guided Therapeutic Strategies
The effectiveness of chemotherapy in colorectal cancer (CRC) is significantly reduced by acquired chemoresistance to 5-fluorouracil (5-FU), oxaliplatin and irinotecan. This structured narrative review synthesises mechanistic, preclinical, translational and clinical evidence underlying resistance to these agents. Distinct drug-specific molecular mechanisms can underlie acquired chemoresistance, whereas shared adaptive survival processes support treatment persistence and may, in some settings, contribute to the emergence of stable acquired resistance. 5-FU resistance is associated with factors such as altered thymidylate synthase activity, drug catabolism, nucleotide metabolism and apoptosis avoidance, whereas resistance to oxaliplatin involves enhanced deoxyribonucleic acid (DNA) repair, detoxification, reduced platinum accumulation and metabolic adaptation. Irinotecan resistance can involve reduced TOP1 expression or TOP1 mutations, altered SN-38 metabolism, increased drug efflux and enhanced tolerance of replication-associated stress. Alongside these drug-proximal mechanisms, drug-tolerant persister states, stem-like programmes, epithelial–mesenchymal plasticity and multidrug-efflux mechanisms can support treatment survival and tumour repopulation. Evidence linking chemoresistance with Wnt/β-catenin, Notch and Hippo/Yes-associated protein 1 (YAP1) signalling is predominantly preclinical and varies according to treatment context, with stronger direct pathway-specific evidence for 5-FU and oxaliplatin than for irinotecan. This distinction allows direct drug-specific associations to be differentiated from broader roles in adaptive survival, cellular plasticity and tumour repopulation after treatment. Cancer-associated fibroblasts, immune and cytokine signalling, extracellular vesicles, hypoxia and treatment-induced remodelling of the tumour microenvironment can all further influence tumour heterogeneity and non-cell-autonomous resistance. Residual disease, resistant cellular states and therapeutically relevant molecular dependencies may be detected or characterised using circulating tumour DNA, pathway-associated biomarkers, patient-derived organoids and emerging resistance-profiling technologies. These findings show that interactions between drug-specific molecular escape mechanisms, adaptive cellular states and the tumour microenvironment contribute to heterogeneous patterns of treatment survival and acquired chemoresistance. The development of molecularly targeted and mechanism-guided strategies for overcoming resistance in CRC may be supported by defining these mechanisms and their associated biomarkers.
Open AccessAcquired Chemoresistance in Colorectal Cancer: Therapy-Induced Signalling Adaptation, Cellular Plasticity and Mechanism-Guided Therapeutic Strategies
The effectiveness of chemotherapy in colorectal cancer (CRC) is significantly reduced by acquired chemoresistance to 5-fluorouracil (5-FU), oxaliplatin and irinotecan. This structured narrative review synthesises mechanistic, preclinical, translational and clinical evidence underlying resistance to these agents. Distinct drug-specific molecular mechanisms can underlie acquired chemoresistance, whereas shared adaptive survival processes support treatment persistence and may, in some settings, contribute to the emergence of stable acquired resistance. 5-FU resistance is associated with factors such as altered thymidylate synthase activity, drug catabolism, nucleotide metabolism and apoptosis avoidance, whereas resistance to oxaliplatin involves enhanced deoxyribonucleic acid (DNA) repair, detoxification, reduced platinum accumulation and metabolic adaptation. Irinotecan resistance can involve reduced TOP1 expression or TOP1 mutations, altered SN-38 metabolism, increased drug efflux and enhanced tolerance of replication-associated stress. Alongside these drug-proximal mechanisms, drug-tolerant persister states, stem-like programmes, epithelial–mesenchymal plasticity and multidrug-efflux mechanisms can support treatment survival and tumour repopulation. Evidence linking chemoresistance with Wnt/β-catenin, Notch and Hippo/Yes-associated protein 1 (YAP1) signalling is predominantly preclinical and varies according to treatment context, with stronger direct pathway-specific evidence for 5-FU and oxaliplatin than for irinotecan. This distinction allows direct drug-specific associations to be differentiated from broader roles in adaptive survival, cellular plasticity and tumour repopulation after treatment. Cancer-associated fibroblasts, immune and cytokine signalling, extracellular vesicles, hypoxia and treatment-induced remodelling of the tumour microenvironment can all further influence tumour heterogeneity and non-cell-autonomous resistance. Residual disease, resistant cellular states and therapeutically relevant molecular dependencies may be detected or characterised using circulating tumour DNA, pathway-associated biomarkers, patient-derived organoids and emerging resistance-profiling technologies. These findings show that interactions between drug-specific molecular escape mechanisms, adaptive cellular states and the tumour microenvironment contribute to heterogeneous patterns of treatment survival and acquired chemoresistance. The development of molecularly targeted and mechanism-guided strategies for overcoming resistance in CRC may be supported by defining these mechanisms and their associated biomarkers.
- Open Access
Heating the Cold: Overcoming Immunotherapy Resistance in Microsatellite-Stable Colorectal Cancer: A Systematic Review
Colorectal cancer (CRC) has shown significant heterogeneity regarding its response to immunotherapy. Long-lasting, beneficial effects have been observed in mismatch repair-deficient, microsatellite instability-high (dMMR/MSI-H) tumours, while mismatch repair-proficient, microsatellite stable (pMMR/MSS) tumours have remained resistant. Such differences in results have been studied in this review through the “hot” and “cold” tumour concept. It explains how various biological and microenvironmental factors play a role in immune resistance and T-cell priming and infiltration. Key factors include a low neoantigen load and defects in antigen presentation, which reduce the overall immune recognition of tumour cells. The review also studies certain processes such as Wnt/β-catenin and mitogen-activated protein kinase (MAPK) signalling and what input they have in the prevention of effective antitumour immune responses. Conventional treatments like chemotherapy and radiotherapy have been considered alongside more targeted treatments such as the inhibition of vascular endothelial growth factor (VEGF) signalling and the suppression of myeloid-mediated immune evasion, to convert “cold” MSS tumours into immune-responsive lesions. Methods which aim to modify the tumour microenvironment such as metabolic reprogramming and microbiome modulation have also been covered in this review. Artificial intelligence and nanomedicine are new technologies that could provide improved patient stratification and therapeutic precision, although their clinical application in pMMR/MSS CRC remains under investigation. A systematic literature search of PubMed and PubMed Central (PMC) was conducted from 10 June 2026 to 19 August 2026 using predefined eligibility criteria, with study selection reported according to PRISMA 2020. Because of substantial heterogeneity in study design, therapeutic approach and reported outcomes, the included evidence was synthesized narratively rather than by meta-analysis. A total of 158 studies were included.
Open AccessHeating the Cold: Overcoming Immunotherapy Resistance in Microsatellite-Stable Colorectal Cancer: A Systematic Review
Colorectal cancer (CRC) has shown significant heterogeneity regarding its response to immunotherapy. Long-lasting, beneficial effects have been observed in mismatch repair-deficient, microsatellite instability-high (dMMR/MSI-H) tumours, while mismatch repair-proficient, microsatellite stable (pMMR/MSS) tumours have remained resistant. Such differences in results have been studied in this review through the “hot” and “cold” tumour concept. It explains how various biological and microenvironmental factors play a role in immune resistance and T-cell priming and infiltration. Key factors include a low neoantigen load and defects in antigen presentation, which reduce the overall immune recognition of tumour cells. The review also studies certain processes such as Wnt/β-catenin and mitogen-activated protein kinase (MAPK) signalling and what input they have in the prevention of effective antitumour immune responses. Conventional treatments like chemotherapy and radiotherapy have been considered alongside more targeted treatments such as the inhibition of vascular endothelial growth factor (VEGF) signalling and the suppression of myeloid-mediated immune evasion, to convert “cold” MSS tumours into immune-responsive lesions. Methods which aim to modify the tumour microenvironment such as metabolic reprogramming and microbiome modulation have also been covered in this review. Artificial intelligence and nanomedicine are new technologies that could provide improved patient stratification and therapeutic precision, although their clinical application in pMMR/MSS CRC remains under investigation. A systematic literature search of PubMed and PubMed Central (PMC) was conducted from 10 June 2026 to 19 August 2026 using predefined eligibility criteria, with study selection reported according to PRISMA 2020. Because of substantial heterogeneity in study design, therapeutic approach and reported outcomes, the included evidence was synthesized narratively rather than by meta-analysis. A total of 158 studies were included.
- Open Access
- 4 September 2026
- Published by MDPI AG in Biophysica
- Vol. 6 (5) , 85
MALDI-Based Multiomics and Spatial Molecular Profiling—Principles, Integrated Workflows, Biomedical Applications, and Future Perspectives: A Systematic Review
Although expression-based omics has greatly contributed to biological research, the biochemical state of cells or tissues cannot be fully explained by transcript or gene expression data alone. This systematic review investigated when matrix-assisted laser desorption/ionisation (MALDI)-based approaches can support the integration of multiple molecular layers and when they remain limited to single-class molecular mapping. PubMed was searched between 1 February and 8 June 2026. English-language peer-reviewed publications relevant to the principles, methods, molecular classes, or biomedical applications of matrix-assisted laser desorption/ionisation-based multiomics were eligible. Publications outside this scope were excluded. Records were independently screened by two reviewers, and disagreements were resolved through discussion. The findings were narratively synthesised based on the analytical platform, molecular layer, integrated spatial multiomics, spatial application, and biomedical use. The methodological quality and risk of bias were not formally assessed, which limits the certainty and strength of the conclusions drawn from this narrative synthesis. Following the reapplication of the relevance criteria, 111 publications from 1633 identified records were included in the final review. The evidence was reclassified and presented separately as true multilayer MALDI studies, MALDI integrated with orthogonal modalities, and background uniomics or spatial molecular profiling studies. These publications included human, animal, cellular, tissue-based, and methodological studies. These publications cover many molecular classes and biomedical applications. As many publications did not involve human participants, a single pooled participant total was not applicable to this study. Matrix-assisted laser desorption/ionisation-based techniques were used to analyse metabolites, lipids, glycans, peptides, and intact proteins in the reviewed literature. The literature also shows that spatial information can be retained using matrix-assisted laser desorption/ionisation imaging mass spectrometry (MALDI-IMS). Its ability to map molecular signals back to specific tissue regions or areas associated with disease supports its potential clinical utility. Specific areas of application, such as cancer, neurological, and infectious disease research, are also reviewed. The use of matrix-assisted laser desorption/ionisation-based techniques for biomarker discovery has been evaluated. Small sample sizes, proof-of-concept designs, inconsistent outcome reporting, and limited external validation have limited the evidence. Technical limitations include ion suppression, limited quantification, sample preparation variability, and differing analyte sensitivity. Emerging developments, such as single-cell imaging and AI analysis, have also been explored. Matrix-assisted laser desorption/ionisation enables multiomics when two or more complementary molecular layers are analysed and integrated within the same biological system. When only a single molecular class is analysed, the approach remains spatial molecular mapping rather than multiomic analysis. However, before matrix-assisted laser desorption/ionisation-based approaches can be applied in routine clinical practice, standardised workflows and better quantitative methods are needed. This review received no external funding and was not registered.
- 4 September 2026
- Published by MDPI AG in Biophysica
- Vol. 6 (5) , 85
Open AccessMALDI-Based Multiomics and Spatial Molecular Profiling—Principles, Integrated Workflows, Biomedical Applications, and Future Perspectives: A Systematic Review
Although expression-based omics has greatly contributed to biological research, the biochemical state of cells or tissues cannot be fully explained by transcript or gene expression data alone. This systematic review investigated when matrix-assisted laser desorption/ionisation (MALDI)-based approaches can support the integration of multiple molecular layers and when they remain limited to single-class molecular mapping. PubMed was searched between 1 February and 8 June 2026. English-language peer-reviewed publications relevant to the principles, methods, molecular classes, or biomedical applications of matrix-assisted laser desorption/ionisation-based multiomics were eligible. Publications outside this scope were excluded. Records were independently screened by two reviewers, and disagreements were resolved through discussion. The findings were narratively synthesised based on the analytical platform, molecular layer, integrated spatial multiomics, spatial application, and biomedical use. The methodological quality and risk of bias were not formally assessed, which limits the certainty and strength of the conclusions drawn from this narrative synthesis. Following the reapplication of the relevance criteria, 111 publications from 1633 identified records were included in the final review. The evidence was reclassified and presented separately as true multilayer MALDI studies, MALDI integrated with orthogonal modalities, and background uniomics or spatial molecular profiling studies. These publications included human, animal, cellular, tissue-based, and methodological studies. These publications cover many molecular classes and biomedical applications. As many publications did not involve human participants, a single pooled participant total was not applicable to this study. Matrix-assisted laser desorption/ionisation-based techniques were used to analyse metabolites, lipids, glycans, peptides, and intact proteins in the reviewed literature. The literature also shows that spatial information can be retained using matrix-assisted laser desorption/ionisation imaging mass spectrometry (MALDI-IMS). Its ability to map molecular signals back to specific tissue regions or areas associated with disease supports its potential clinical utility. Specific areas of application, such as cancer, neurological, and infectious disease research, are also reviewed. The use of matrix-assisted laser desorption/ionisation-based techniques for biomarker discovery has been evaluated. Small sample sizes, proof-of-concept designs, inconsistent outcome reporting, and limited external validation have limited the evidence. Technical limitations include ion suppression, limited quantification, sample preparation variability, and differing analyte sensitivity. Emerging developments, such as single-cell imaging and AI analysis, have also been explored. Matrix-assisted laser desorption/ionisation enables multiomics when two or more complementary molecular layers are analysed and integrated within the same biological system. When only a single molecular class is analysed, the approach remains spatial molecular mapping rather than multiomic analysis. However, before matrix-assisted laser desorption/ionisation-based approaches can be applied in routine clinical practice, standardised workflows and better quantitative methods are needed. This review received no external funding and was not registered.
- Open Access
From Phytotoxin to Cell-Death Probe: Ophiobolin A and Related Sesterterpenoids in Membrane Stress and Non-Apoptotic Cell Death
Ophiobolin A is a fungal sesterterpenoid initially characterised as a phytotoxin but progressively investigated for its biomedical significance due to its potent and mechanistically characteristic cellular activities. In this review, Ophiobolin A is discussed within the wider landscape of natural products as a source of bioactive molecular scaffolds, and current knowledge on its structural features, biosynthesis, chemical synthesis, semi-synthetic modification, and in vitro biological applications is summarised. Evidence drawn from chemical, biochemical, and cell biology studies is integrated to describe the distinctive 5-8-5 tricyclic scaffold, the electrophilic dicarbonyl motif, and their roles in covalent modification of cellular components. Collectively, the reviewed evidence underscores that Ophiobolin A and its derivatives trigger both apoptotic and non-apoptotic cell death pathways. These include paraptosis-like death, which is a regulated form of cell death not associated with apoptosis that is defined by major cytoplasmic vacoulisation. This commonly occurs in apoptosis-resistant cancer models via disruption of membrane lipid homeostasis, calmodulin-dependent signalling, mitochondrial function, and proteostasis. Structure–activity relationship studies show that modulation of electrophilicity, oxidation state, and peripheral functionality enables tuning of potency, selectivity, and traceability while retaining key phenotypes. In addition to anticancer effects, antimicrobial and anti-inflammatory activities are also briefly summarised. Taken together, the literature supports Ophiobolin A as a useful molecular probe for considering cell death mechanisms and as a chemically complex yet suitable starting point for derivative development, while reinforcing the need for improved selectivity, delivery strategies, and in vivo validation to further translational potential.
Open AccessFrom Phytotoxin to Cell-Death Probe: Ophiobolin A and Related Sesterterpenoids in Membrane Stress and Non-Apoptotic Cell Death
Ophiobolin A is a fungal sesterterpenoid initially characterised as a phytotoxin but progressively investigated for its biomedical significance due to its potent and mechanistically characteristic cellular activities. In this review, Ophiobolin A is discussed within the wider landscape of natural products as a source of bioactive molecular scaffolds, and current knowledge on its structural features, biosynthesis, chemical synthesis, semi-synthetic modification, and in vitro biological applications is summarised. Evidence drawn from chemical, biochemical, and cell biology studies is integrated to describe the distinctive 5-8-5 tricyclic scaffold, the electrophilic dicarbonyl motif, and their roles in covalent modification of cellular components. Collectively, the reviewed evidence underscores that Ophiobolin A and its derivatives trigger both apoptotic and non-apoptotic cell death pathways. These include paraptosis-like death, which is a regulated form of cell death not associated with apoptosis that is defined by major cytoplasmic vacoulisation. This commonly occurs in apoptosis-resistant cancer models via disruption of membrane lipid homeostasis, calmodulin-dependent signalling, mitochondrial function, and proteostasis. Structure–activity relationship studies show that modulation of electrophilicity, oxidation state, and peripheral functionality enables tuning of potency, selectivity, and traceability while retaining key phenotypes. In addition to anticancer effects, antimicrobial and anti-inflammatory activities are also briefly summarised. Taken together, the literature supports Ophiobolin A as a useful molecular probe for considering cell death mechanisms and as a chemically complex yet suitable starting point for derivative development, while reinforcing the need for improved selectivity, delivery strategies, and in vivo validation to further translational potential.
- Open Access
Nanomedicine in Ovarian Cancer: Advances in Imaging, Targeted Delivery, and Theranostic Therapeutic Platforms
Ovarian cancer continues to be the most lethal gynaecological malignancy, principally due to its late-stage diagnosis, extensive peritoneal dissemination, chemoresistance, and limitations of current imaging and therapeutic strategies. By optimising pharmacokinetics, refining tumour-selective drug delivery, and supporting high-resolution, multimodal imaging, nanomedicine offers a versatile platform to address these limitations. In this review, current progress across lipid-based, polymeric, inorganic, hybrid, and biomimetic nanocarriers is synthesised, emphasising how tailored physiochemical properties, surface functionalisation, and stimuli-responsive designs can improve tumour localisation, surmount stromal and ascetic barriers, and enable controlled drug release. Concurrently, significant advancement in imaging nanoprobes, including magnetic resonance imaging (MRI), positron emission tomography (PET)/single-photon emission computed tomography (SPECT), optical, near-infrared imaging (NIR), ultrasound, and photoacoustic systems, has evolved early lesion detection, intraoperative guidance, and quantitative monitoring of treatment. Diagnosis and therapy are further integrated within single platforms by emerging theranostic constructs, encouraging real-time visualisation of drug distribution and treatment response. Additionally, immune-nanomedicine, intraperitoneal depot systems, and nucleic acid-centred nanotherapies offer promising strategies to address immune suppression and molecular resistance in advanced ovarian cancer. In spite of noteworthy achievements, clinical translation is limited by complex manufacturing requirements, challenges with safety and stability, and restricted patient stratification. To unlock the full clinical potential of nanotechnology in ovarian cancer management, constant innovation in scalable design, regulatory standardisation, and integration of precision biomarkers will be necessary.
Open AccessNanomedicine in Ovarian Cancer: Advances in Imaging, Targeted Delivery, and Theranostic Therapeutic Platforms
Ovarian cancer continues to be the most lethal gynaecological malignancy, principally due to its late-stage diagnosis, extensive peritoneal dissemination, chemoresistance, and limitations of current imaging and therapeutic strategies. By optimising pharmacokinetics, refining tumour-selective drug delivery, and supporting high-resolution, multimodal imaging, nanomedicine offers a versatile platform to address these limitations. In this review, current progress across lipid-based, polymeric, inorganic, hybrid, and biomimetic nanocarriers is synthesised, emphasising how tailored physiochemical properties, surface functionalisation, and stimuli-responsive designs can improve tumour localisation, surmount stromal and ascetic barriers, and enable controlled drug release. Concurrently, significant advancement in imaging nanoprobes, including magnetic resonance imaging (MRI), positron emission tomography (PET)/single-photon emission computed tomography (SPECT), optical, near-infrared imaging (NIR), ultrasound, and photoacoustic systems, has evolved early lesion detection, intraoperative guidance, and quantitative monitoring of treatment. Diagnosis and therapy are further integrated within single platforms by emerging theranostic constructs, encouraging real-time visualisation of drug distribution and treatment response. Additionally, immune-nanomedicine, intraperitoneal depot systems, and nucleic acid-centred nanotherapies offer promising strategies to address immune suppression and molecular resistance in advanced ovarian cancer. In spite of noteworthy achievements, clinical translation is limited by complex manufacturing requirements, challenges with safety and stability, and restricted patient stratification. To unlock the full clinical potential of nanotechnology in ovarian cancer management, constant innovation in scalable design, regulatory standardisation, and integration of precision biomarkers will be necessary.